Two Sigma Investments LP Raises Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Two Sigma Investments LP boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 5.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 154,505 shares of the company's stock after buying an additional 8,476 shares during the quarter. Two Sigma Investments LP owned 0.50% of Medpace worth $51,331,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Invesco Ltd. raised its stake in shares of Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after acquiring an additional 519,186 shares during the period. Proficio Capital Partners LLC boosted its position in shares of Medpace by 34,497.4% during the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock worth $80,575,000 after purchasing an additional 241,827 shares during the period. Raymond James Financial Inc. acquired a new stake in Medpace in the 4th quarter valued at approximately $78,144,000. Norges Bank purchased a new stake in Medpace in the fourth quarter valued at approximately $69,859,000. Finally, GW&K Investment Management LLC raised its position in Medpace by 93.9% in the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after purchasing an additional 133,379 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

MEDP stock opened at $305.98 on Tuesday. The company's 50 day moving average price is $303.87 and its 200 day moving average price is $327.76. The firm has a market capitalization of $8.79 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the prior year, the firm posted $3.20 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares in the company, valued at $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on MEDP shares. Truist Financial lowered their price target on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research report on Wednesday, April 23rd. William Blair restated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Leerink Partners began coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Mizuho reduced their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Finally, TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and lowered their price objective for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.